Earnings
Home›Earnings›Previews›AstraZeneca COPD drug gets two late-stage trial wins w…
AstraZeneca COPD drug gets two late-stage trial wins with full data
The company’s peak annual sales forecast points to more than $5 billion if the therapy meets expectations.
AstraZeneca has received full data from two late-stage trials of its chronic obstructive pulmonary disease, or COPD, drug, with results described as two additional late-stage wins, according to CNBC Markets and CNBC World.
The updated full dataset reinforces hopes the treatment could become a breakthrough COPD option, setting up the potential to contribute to AstraZeneca’s peak annual sales forecast of more than $5 billion.
CNBC Markets and CNBC World said the latest trial wins support the company’s blockbuster hopes as the therapy advances on the late-stage track.